Published in Curr Opin HIV AIDS on July 01, 2006
Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity (2003) 6.19
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity (2008) 5.22
Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med (2008) 4.55
Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals. J Immunol (2005) 2.87
Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci U S A (2004) 2.51
Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabey and nonnatural rhesus macaque hosts. J Virol (2005) 2.48
Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med (2005) 2.43
Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat Med (2002) 2.20
The AIDS resistance of naturally SIV-infected sooty mangabeys is independent of cellular immunity to the virus. Blood (2006) 1.94
Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges. PLoS Med (2005) 1.85
The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines. Expert Rev Vaccines (2004) 1.71
Detection of acute HIV infections in an urban HIV counseling and testing population in the United States. J Acquir Immune Defic Syndr (2007) 1.71
Turnover of lymphocytes and conceptual paradigms in HIV infection. J Clin Invest (2003) 1.69
Short-lived infected cells support virus replication in sooty mangabeys naturally infected with simian immunodeficiency virus: implications for AIDS pathogenesis. J Virol (2008) 1.51
Depletion of CD8+ cells in sooty mangabey monkeys naturally infected with simian immunodeficiency virus reveals limited role for immune control of virus replication in a natural host species. J Immunol (2007) 1.50
Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication. J Clin Invest (2004) 1.48
Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect Dis (2004) 1.46
Roles of target cells and virus-specific cellular immunity in primary simian immunodeficiency virus infection. J Virol (2004) 1.29
A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol (2003) 1.28
Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor. J Virol (2005) 1.27
Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homing. Virology (2007) 1.26
Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression. J Immunol (2009) 1.19
Estimating the effectiveness of simian immunodeficiency virus-specific CD8+ T cells from the dynamics of viral immune escape. J Virol (2007) 1.14
Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol (2008) 1.12
Viral CTL escape mutants are generated in lymph nodes and subsequently become fixed in plasma and rectal mucosa during acute SIV infection of macaques. PLoS Pathog (2011) 1.06
HIV escape: there and back again. Nat Med (2004) 1.03
Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines. Vaccine (2013) 0.90
Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies. PLoS One (2009) 0.90
Selective removal of stratum corneum by microdermabrasion to increase skin permeability. Eur J Pharm Sci (2009) 0.90
Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen. AIDS (2003) 0.89
Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective. Curr Opin HIV AIDS (2010) 0.87
Distinctive TLR7 signaling, type I IFN production, and attenuated innate and adaptive immune responses to yellow fever virus in a primate reservoir host. J Immunol (2011) 0.87
Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol (2012) 0.87
HIV tropism and CD4+ T-cell depletion. Nat Med (2002) 0.84
T(S) cells and immune tolerance induction: a regulatory renaissance? Nat Immunol (2002) 0.84
AIDS vaccine development: the long and winding road. AIDS Rev (2003) 0.84
Contribution of peaks of virus load to simian immunodeficiency virus pathogenesis. J Virol (2002) 0.84
SIVsm quasispecies adaptation to a new simian host. PLoS Pathog (2005) 0.82
Adaptation of a diverse simian immunodeficiency virus population to a new host is revealed through a systematic approach to identify amino acid sites under selection. Mol Biol Evol (2006) 0.80
Assessment of lymphocyte-mediated cytotoxicity using flow cytometry. Methods Mol Biol (2004) 0.79
Born this way? Understanding the immunological basis of effective HIV control. Nat Immunol (2012) 0.78
Evaluating the health impact of a public-private partnership: to reduce rotavirus disease in Nicaragua. Hum Vaccin Immunother (2012) 0.78